Addex Therapeutics and Indivior announced the selection of clinical candidates from their GABAB positive allosteric modulator research collaboration. Indivior has chosen a compound for substance use disorder development, while Addex selected a candidate for chronic cough treatment. Under the agreement, Addex is eligible for up to $330 million in milestone payments plus tiered royalties ranging from high single digits to low double-digits on net sales.The collaboration, spanning over five years, leveraged Addex's industrial-scale allosteric modulator discovery platform to identify specific candidates from thousands of compounds. Indivior will undertake all future development of their selected compound, with IND enabling studies expected to begin in H1 2025. Addex plans to advance its chronic cough candidate into IND enabling studies in 2025.GABAB receptor activation, validated both clinically and commercially, shows promise in treating multiple conditions including alcohol use disorder, CMT1A, overactive bladder, and pain. PAMs are expected to deliver efficacy with fewer adverse effects than traditional agonists like baclofen, as they only act when the natural ligand activates the receptor.

Addex Therapeutics and Indivior announced the selection of clinical candidates from their GABAB positive allosteric modulator research collaboration. Indivior has chosen a compound for substance use disorder development, while Addex selected a candidate for chronic cough treatment. Under the agreement, Addex is eligible for up to $330 million in milestone payments plus tiered royalties ranging from high single digits to low double-digits on net sales.The collaboration, spanning over five years, leveraged Addex's industrial-scale allosteric modulator discovery platform to identify specific candidates from thousands of compounds. Indivior will undertake all future development of their selected compound, with IND enabling studies expected to begin in H1 2025. Addex plans to advance its chronic cough candidate into IND enabling studies in 2025.GABAB receptor activation, validated both clinically and commercially, shows promise in treating multiple conditions including alcohol use disorder, CMT1A, overactive bladder, and pain. PAMs are expected to deliver efficacy with fewer adverse effects than traditional agonists like baclofen, as they only act when the natural ligand activates the receptor.